Semaglutide (Wegovy) cut the risk for major heart events in people with obesity and cardiovascular disease regardless of how much weight they lost. (The Lancet…
Source link : https://www.medpagetoday.com/primarycare/obesity/118099
Author :
Publish date : 2025-10-23 13:25:00
Copyright for syndicated content belongs to the linked Source.